...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer
【24h】

Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer

机译:长时间散布的核元素1低甲基化是IA期非小细胞肺癌预后不良的标志

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Global hypomethylation and the hypermethylation of gene promoter regions are common events in tumor DNA. The aim of this study was to evaluate the prognostic significance of both global hypomethylation and gene promoter hypermethylation in DNA from non-small cell lung cancer (NSCLC). Experimental Design: Genomic DNA was obtained from the tumor tissue of 379 NSCLC patients who underwent surgery. Methylation levels were measured by real-time PCR following bisulfite modification of DNA and were correlated with clinicopathologic parameters and patient prognosis. Methylation of long interspersed nuclear element 1 (LINE-1) was used as a surrogate marker for global methylation. Hypermethylation of the APC, CDH13, and RASSF1 promoter regions was also evaluated. Results: Tumor tissue showed significantly higher CDH13 and RASSF1 methylation levels compared with normal lung tissue, but lower LINE-1 methylation levels. APC, RASSF1, and LINE-1 methylation levels were significant prognostic factors in univariate analysis of an initial cohort of 234 cases. APC and LINE-1 methylation remained significant prognostic factors in multivariate analysis that included age, gender, smoking history, histologic type, and pathologic stage. LINE-1 methylation showed marginally significant prognostic value in stage IA and IB disease. Expansion of the study cohort to 364 cases revealed that LINE-1 methylation had significant prognostic value for stage IA NSCLC patients in multivariate analysis. Conclusions: LINE-1 hypomethylation was an independent marker of poor prognosis in stage IA NSCLC. Validation of this finding in additional tumor cohorts could have clinical relevance for the management of early-stage NSCLC.
机译:目的:整体低甲基化和基因启动子区域的高甲基化是肿瘤DNA中的常见事件。本研究的目的是评估非小细胞肺癌(NSCLC)DNA中总体低甲基化和基因启动子高甲基化的预后意义。实验设计:从379例接受手术的NSCLC患者的肿瘤组织中获得基因组DNA。亚硫酸氢盐修饰DNA后,通过实时PCR测定甲基化水平,并将其与临床病理参数和患者预后相关。长散布的核元素1(LINE-1)的甲基化被用作整体甲基化的替代标记。还评估了APC,CDH13和RASSF1启动子区域的超甲基化。结果:与正常肺组织相比,肿瘤组织显示出CDH13和RASSF1甲基化水平明显升高,但LINE-1甲基化水平降低。 APC,RASSF1和LINE-1甲基化水平是234例初始队列的单因素分析中的重要预后因素。在多变量分析中,APC和LINE-1甲基化仍然是重要的预后因素,包括年龄,性别,吸烟史,组织学类型和病理分期。 LINE-1甲基化在IA和IB期疾病中显示出微不足道的预后价值。研究队列扩展至364例患者,结果表明,在多因素分析中,LINE-1甲基化对IA期NSCLC患者具有显着的预后价值。结论:LINE-1低甲基化是IA期NSCLC预后不良的独立标志。在其他肿瘤队列中验证这一发现可能与早期NSCLC的治疗具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号